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Introduction
Endothelial cells (ECs) lining the vasculature display a large degree 
of phenotypic variation and molecular heterogeneity, reflecting 
the vastly different environmental milieus and functions of target 
end organs (1, 2). Homeostatic maintenance of a differentiated 
state within distinct organ environments is, by necessity, an active 
process that requires consistent activation or suppression of key 
signaling pathways. In contrast, physiological changes or disease 
conditions can disrupt these pathways, resulting in the loss of a 
differentiated state. Endothelial to mesenchymal transition and 
endothelial to hematopoietic transition remain striking examples 
of the extent to which endothelial cells may be altered from their 
formally differentiated, homeostatic states.
Intraendothelial transitions also occur, as exemplified by in 
vivo deletion of the lymphatic-fating nuclear receptor Prox1 in 
mouse lymphatic endothelial cells (LECs), resulting in a reduction 
of LEC identity with a concomitant enhancement of blood endo-
thelial cell (BEC) identity (3). Inversely, BEC-specific PROX1 ecto-
pic expression upregulates lymphatic genes while downregulating 
BEC-specific genes (4). Indeed, some structures exhibit an identi-
ty that is hybrid of both blood and lymphatic markers, such as the 
Schlemm’s canal of the eye or the ascending vasa recta of the kid-
ney, to ultimately underlie their highly specialized functions (5–7). 
It is likely that other hybrid vessels exist, but our understanding 
of the molecular markers and regulators of this organ- and ves-
sel-specific endothelial plasticity remains limited.
One vessel that exhibits a high degree of plasticity is found in 
the specialized vascular bed of the placenta. Spiral arteries (SAs) 
of the maternal decidua dynamically regulate blood flow into the 
placenta to meet the ever-evolving nutritional and oxygenation 
needs of a growing fetus. During early to mid-gestation, SAs under-
go remodeling characterized by luminal expansion facilitated by a 
combination of endothelial proliferation, degradation of extracellu-
lar matrix, and loss of smooth muscle coverage (8, 9). In humans, 
poor or failed spiral artery remodeling (SAR) is associated with pre-
eclampsia, a potentially fatal hypertensive disease that occurs in 
2%–8% of pregnancies, often causing fetal growth restriction and 
long-term health complications for both mother and fetus (10–12). 
Thus, there is great interest in elucidating the pregnancy-induced 
factors that serve as molecular determinants of SAR, with a partic-
ular focus on the crosstalk between SA endothelial cells and locally 
secreted trophoblast- and immune-cell factors.
Several studies have correlated an endothelial transition 
of SAs from arterial to venous fate during SAR, as evidenced by 
changes in the receptor tyrosine kinase family of ephrin recep-
tors (13), which also have critical functions in lymphatic vessels 
(14–16). Moreover, in the early mouse implantation site, the vas-
cular fold anlage of SAs also express high levels of VEGFR3 and 
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Figure 1. SAs acquire lymphatic characteristics during SAR. (A) Tissue sections of mouse placenta at time points before and after SAR. PROX1 is spo-
radically expressed at low levels on the SA endothelium at E11.5 and E13.5 (per embryonic day, n = 7–9 total placentas from 3 litters, with 1–4 placentas 
from each litter).  White arrowheads mark PROX1+ nuclei. Scale bars: 20 μm. (B) PROX1-RFP+ SA endothelium at E11.5 and E13.5.  Scale bars: 50 μm. (C and 
D) LYVE1 and VEGFR3 expression is low or absent in SAs at E11.5, but are highly expressed at E13.5 (per embryonic day, n = 8–12 total placentas from 3–4 
litters, with 2–4 placentas from each litter). Scale bars: 50 μm. (E) Tissue sections of rat placenta at E11.5 show absent VEGFR3 expression while at E13.5 
and E18.5 there is robust VEGFR3 expression in SAs. Cytokeratin 7+ (CK7) invasive trophoblasts do not express VEGFR3 (per embryonic day, n = 4–6 total 
placentas from 3 litters, with 1–2 placentas from each litter). Scale bars: 100 μm. (F) A model summarizing features of lymphatic mimicry in SAs during 
remodeling. SMC, smooth muscle cell.
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did not express LYVE1 (Supplemental Figure 2F), illustrating spe-
cies variation in vessel heterogeneity. Taken together, these data 
demonstrate that SAs acquire a hybrid vessel identity during SAR, 
expressing both blood EC and lymphatic EC markers (Figure 1F), 
similar to Schlemm’s canal (5, 6).
Mice deficient in uNK cells lack p-ERK signaling in VEGFR3- 
expressing SA endothelial cells. Many studies on SAR have focused 
on how the local interstitial cells, such as uNK cells, promote the 
remodeling process. Indeed, mice lacking uNK cells have impaired 
SAR, retaining SA SMCs and thickened vessels walls (24). uNK 
cells secrete matrix metalloproteases and endothelial growth fac-
tors, including vascular endothelial growth factor C (VEGFC), a 
key driver of lymphangiogenesis that signals through VEGFR3 (17, 
25, 26). Since we have found the expression of endothelial VEGFR3 
in SAs to be coincident with the loss of SMC coverage, we hypoth-
esized that uNK cell secretion of VEGFC may be contributing to 
the removal of SMCs during SAR. Thus, we utilized Il2rγtm1Wjl mice 
which are devoid of uNK cells (24) and evaluated their SA endo-
thelial cells for p-ERK as an indicator of endothelial activation. 
First, we confirmed that Il2rγtm1Wjl mice lacked uNK cells in the 
mesometrial decidua (Figure 2A) and retained aberrant SMC cov-
erage at E13.5 (Figure 2B). Despite this SMC retention, we found 
that the SAs of Il2rγtm1Wjl placentas still upregulated VEGFR3 level 
at E13.5, compared with controls (Figure 2B). Congruent with the 
timing of SAR and absence of VEGFR3 expression, we found low 
levels of p-ERK in the SA endothelium of both WT and Il2rγtm1Wjl 
mice at E11.5 (Figure 2C). However, while WT VEGFR3-expressing 
SAs showed a robust increase in p-ERK staining at E13.5, there was 
no significant increase in Il2rγtm1Wj SAs (Figure 2, C and D) despite 
similar VEGFR3 expression (Figure 2E), demonstrating that the 
absence of uNK cells abrogates signaling within VEGFR3-express-
ing endothelial cells. Until now, the main function of uNK cells 
during SAR was thought to be related to extracellular matrix deg-
radation and disruption of vessel wall SMCs (25). These data reveal 
that uNK cells also communicate with the endothelium, which pro-
motes ERK signaling, likely in part through VEGFR3, but could also 
be coincident with other activated pathways.
Mice with kinase-dead VEGFR3 poorly remodel their spiral arter-
ies and exhibit fetal growth restriction. To directly assess the role of 
VEGFR3 during SAR, we analyzed SAs of heterozygous Flt4Chy/+ 
mice, which carry a dominant-negative, kinase-dead mutation, 
effectively blocking ligand-mediated receptor autophosphory-
lation (27, 28). Homozygous animals for this Flt4 (also known as 
Vegfr3) point mutation show complete lack of lymphatics and die 
immediately after birth due to respiratory failure, but the hetero-
zygotes survive with some lymphatic deficiencies, including chy-
lous ascites from which chy is derived (29). We first confirmed that 
there was no significant difference in uNK cell number or density 
in the decidua of Flt4Chy/+ mice compared with WT mice (Figure 3, 
A and B), and that VEGFR3 was still expressed in Flt4Chy/+ SAs, sim-
ilar to WT SAs (Figure 3C). To determine whether endothelial sig-
naling is disrupted like in Il2rγtm1Wjl SAs, we examined endothelial 
ERK phosphorylation and found Flt4Chy/+ SAs to have blunted ERK 
phosphorylation at E13.5 compared with WT controls (Figure 3D). 
To assess spiral artery remodeling, we next compared the SMC 
coverage, luminal area, and vessel wall thickness of Flt4Chy/+ SAs to 
WT SAs. While no significant difference was observed before SAR 
calcitonin receptor–like receptor (CLR), receptors for the potent 
lymphangiogenic factors VEGFC and adrenomedullin (AM), 
respectively (17–19). And although some studies have conclud-
ed that the mouse placenta does not contain classical lymphatic 
vessels (20, 21), the high placental expression and requirement of 
these lymphangiogenic factors during SAR (19, 22) prompted us 
to ask whether SAs initiate an intraendothelial transition toward 
lymphatic fate as a mechanism to promote remodeling.
Results
SAs acquire expression of a subset of lymphatic markers during SAR. 
Remodeled SAs have remarkable similarities to lymphatic vessels, 
including reduced smooth muscle cell (SMC) coverage, lack of a 
basement membrane, and a large and dilated lumen, permitting 
low-resistance, high-capacitance flow of oxygenated blood to 
the placenta. This prompted us to question whether SAs might 
adopt lymphatic identity characteristics during remodeling. Using 
immunohistochemistry to identify lymphatic markers in SAs of 
mouse and rat placentas, we found punctate PROX1 expression 
in mouse SA endothelium prior to SAR at E11.5 and after SAR at 
E13.5 (Figure 1A). Using a reporter mouse expressing red fluores-
cent protein (RFP) under the Prox1 promoter, Tg(Prox1-tdTomato) 
12Nrud/J, we observed robust RFP expression in SAs at E11.5 and 
E13.5 (Figure 1B), though the relative expression level was lower 
than that observed in bona fide lymphatic vessels of the adja-
cent myometrium (Supplemental Figure 1A; supplemental mate-
rial available online with this article; https://doi.org/10.1172/
JCI120446DS1). Interestingly, LYVE1 was absent at E11.5, but 
induced during the remodeling phase at E13.5 (Figure 1C). Giv-
en that LYVE1 is also expressed in some macrophages, we ruled 
out the possibility that these LYVE1+ cells may be myeloid derived 
(Supplemental Figure 1, B and C).
VEGFR3 expression was also low or absent in SAs at E11.5, but 
then robustly induced by E13.5 throughout the SA endothelium 
(Figure 1D). Consistently, VEGFR3 expression was concomitant 
with remodeled regions of the SA, as evidenced by reduced SMC 
coverage determined by smooth muscle actin (αSMA) staining (Fig-
ure 1, B–D, and Supplemental Figure 1D). VEGFR3 was also detect-
ed in the vascular zone, sometimes referred to as vascular sinuses, 
of the decidua as previously reported (Supplemental Figure 1E and 
ref. 23). Some lymphatic markers were not detected in SAs, notably 
NRP2, PDPN, CCL21, and endomucin (Supplemental Figure 2, 
A–D), while PECAM-1 expression was detected from E11.5 to E13.5 
(Supplemental Figure 2E).
In humans and rats, but less so in mice, endovascular tro-
phoblast invasion is a prominent feature of SAR. Thus, we also 
characterized SAs from rat placentas where remodeling events 
occur on a similar gestational timescale to mice. As observed in 
mice, we identified the initiation of prominent VEGFR3 expres-
sion between E11.5 to E13.5 which was concomitant with SMC 
loss, and the expression was maintained through to E18.5 (Fig-
ure 1E). Invading trophoblasts (cytokeratin 7+), which can invade 
intraluminally as early as E11.5 and interstitially from between 
E14.5 to E18.5 in rats, were not a source of VEGFR3 expression 
in rat SAs, as evident by a lack of colocalized expression (Figure 
1E). As observed in mice, the vascular zone in rats also expresses 
VEGFR3 (Supplemental Figure 2F). In contrast to mouse, rat SAs 
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We next sought to determine if the Flt4Chy/+ mice exhibit symp-
toms of preeclampsia during pregnancy. It is established that 
impaired SAR alone is insufficient to induce symptoms of pre-
eclampsia in mice (30). However, other models of preeclampsia 
have previously been established in mice (31–33), and additional 
unknown factors could be at play in Flt4Chy/+ mice. So, we evalu-
ated multiple symptoms of preeclampsia including hypertension, 
glomerular defects, proteinuria, and fetal growth restriction. We 
found no significant differences in blood pressure from E15.5 to 
(at E11.5), by E13.5 Flt4Chy/+ SAs retained significantly more SMC 
coverage and failed to undergo the typical increase in luminal area 
characteristic of SAR and observed in WT SAs (Figure 3, E–G). Fur-
thermore, histological and morphometric analysis revealed that 
the walls of Flt4Chy/+ SAs remained significantly thickened at E13.5 
compared with WT SAs (Figure 3, F and H), likely due in part to the 
SMC retention, indicating incomplete vessel remodeling. Togeth-
er, these data establish VEGFR3 signaling as a necessary pathway 
for promoting spiral artery remodeling.
Figure 2. Endothelial ERK activation during SAR is blunted in uNK-deficient mice. (A) Il2rγtm1Wjl mice do not have DBA lectin+ uNK cells in the mesometrial 
lymphoid aggregate of pregnancy (MLAp) and decidua basalis (DB) (per group, n = 6 total placentas from 3 litters with 2 placentas from each litter). JZ, 
junctional zone. Scale bars: 300 μm. (B) WT SAs exhibit increased VEGFR3 expression and loss of smooth muscle cells from E11.5 to E13.5. Il2rγtm1Wjl SAs 
have VEGFR3 expression at E13.5, but SMC coverage remains high. Scale bars: 50 μm. (C) p-ERK staining increases in the SA endothelium from E11.5 to 
E13.5 in WT, but not in Il2rγtm1Wjl mice. Scale bars: 50 μm. (D) Quantification of p-ERK and (E) VEGFR3 mean fluorescence intensity (MFI) in the SA endo-
thelium of WT and Il2rγtm1Wjl placentas at E11.5 and E13.5 (per group, n = 6–7 total placentas from 3 litters with 1–3 placentas from each litter; 2-way ANOVA 
with Bonferroni posttest, P < 0.0001 for D and E). In all graphs, the red horizontal line represents the mean. ***P < 0.001 versus control.
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Figure 3. Loss of VEGFR3 signaling is sufficient to impair SAR. (A and B) The density of uNK cells in the placental decidua of Flt4Chy/+ mice is similar to 
WT at E13.5 (per group, n = 6 total placentas from 3 litters with 2 placentas from each litter; unpaired t test). (C) VEGFR3 signaling–deficient Flt4Chy/+ 
mice retain more SA SMC coverage (blue) compared with WT, even while total expression of VEGFR3 is unchanged. (D) Quantification of endothelial ERK 
phosphorylation (p-ERK) of WT and Flt4Chy/+ mice at E13.5 (per group, n = 5 total placentas from 3 litters with 1–2 placentas from each litter; 2-way ANOVA 
with Bonferroni posttest, P = 0.0002). (E) Quantification of the percentage of SA perimeter covered in αSM-actin+ SMCs of WT and Flt4Chy/+ mice at E13.5 
(per group, n = 6–9 total placentas from 3 litters with 2–3 placentas from each litter; 2-way ANOVA with Bonferroni posttest, P = 0.0001). (F) H&E staining 
of SAs in WT and Flt4Chy/+ mice at E11.5 and E13.5. (G and H) Quantification of the luminal area and wall thickness (ratio of vessel wall to lumen area) of 
SAs in WT and Flt4Chy/+ mice at E11.5 and E13.5 (per group, n = 21–35 total placentas from 3 litters with 4–13 placentas from each litter; 2-way ANOVA with 
Bonferroni posttest, P < 0.0001 for G and H). (I–K) Flt4Chy/+ mice exhibit fetal growth restriction and increased placental weights at E18.5 (per genotype, n = 
33–44 total embryos and placentas from 3 litters with 9–16 embryos from each litter; unpaired t test). All scale bars: 50 μm. In all graphs the red horizontal 
line represents the mean. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 versus control.
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E18.5 between Flt4Chy/+ and WT pregnant mice (Supplemental 
Figure 3A). Nor did we find any indication of renal dysfunction; 
no difference was observed in kidney weights, glomerulus size, 
or Bowman’s space area at E18.5 (Supplemental Figure 3, B–E). 
There was also no difference in the urinary protein concentration 
at E16.5 (Supplemental Figure 3F). These data demonstrate that 
Flt4Chy/+ mice do not exhibit overt clinical symptoms of preeclamp-
sia. However, when we examined fetal and placental weights we 
found significant fetal growth restriction and increased placental 
weights (Figure 3, I–K), entirely consistent with what has been 
observed in some uNK cell–deficient mouse models and support-
ing the conclusion that Flt4Chy/+ mice exhibit pregnancy deficits 
compatible with insufficient SAR (34, 35).
uNK cell–conditioned medium activates VEGFR3. Given that 
both VEGFR3 and uNK cells contribute to SA SMC regulation 
during remodeling, and that uNK cells promote downstream 
endothelial ERK signaling at the time in which VEGFR3 is initially 
expressed (Figure 2, C and D), we reasoned that uNK cells may be 
secreting factors that capitalize upon the newly acquired lymphatic 
mimicry of SAs. Therefore, we generated uNK-conditioned medi-
um (uNK-CM) by isolating and culturing murine uNKs in vitro as 
previously described (36), and treated human LECs with this uNK-
CM to assess VEGFR3 activation. We first confirmed the presence 
of VEGFC in uNK-CM by ELISA and found an average of 8.919 ng/
mL of VEGFC (± 0.836 ng/mL). We then confirmed that mouse 
VEGFC does activate human VEGFR3, as indicated by an increase 
in p-VEGFR3 immunostaining compared with control medium 
(Figure 4, A and B, and ref. 37). Using a phospho-specific antibody 
for VEGFR3 at Tyr1230/1231, we found a significant increase in 
p-VEGFR3 signal in uNK-CM–treated LECs compared with LECs 
treated with unconditioned control medium (Figure 4, A and B). 
When uNK-CM–treated LECs were cotreated with sunitinib, an 
inhibitor of ligand-mediated VEGFR3 autophosphorylation, the 
p-VEGFR3 signal returned to baseline. These data establish that 
uNK cells secrete factors that can activate VEGFR3, with VEGFC 
being the most likely candidate for ligand-mediated autophosphor-
ylation of residues Tyr1230/1231 (38).
Immune cell–derived VEGFC promotes spiral artery remodel-
ing. To determine whether uNK-derived VEGFC is necessary 
to activate the SA endothelium and promote SAR, we examined 
SAs in Vegfcfl/fl Vav1-Cre mice (Supplemental Figure 4), which do 
not express VEGFC from immune cells. Even though the Cre is 
immune cell–targeted, we did not find any significant difference 
in Vegfcfl/fl Vav1-Cre uNK density in the mesometrial decidua com-
pared with Vegfcfl/fl controls (Figure 5, A and B). Similarly to the 
Flt4Chy/+ SAs, Vegfcfl/fl Vav1-Cre SAs have increased SMC retention 
compared with Vegfcfl/fl SAs at E13.5 (Figure 5, C and D). Fur-
thermore, lumen area was blunted in Vegfcfl/fl Vav1-Cre SAs while 
the relative wall area increased compared with Vegfcfl/fl control 
SAs (Figure 5, E–G). Together, these findings replicate what was 
observed in Flt4Chy/+ SAs at E13.5, supporting that VEGFC is direct-
ly communicating with the SA endothelium via direct activation 
of VEGFR3 to help promote SAR. Notably, the blunted SAR is con-
sistent with what has been observed in immunodeficient mouse 
lines, suggesting that VEGFC expression is fundamental to the 
role uNK cells play to promote SAR in the placenta.
Discussion
In summary, we have identified a novel instance of lymphatic mim-
icry within the SAs of the decidua, whereby SAs acquire expression 
of lymphatic markers, particularly VEGFR3, to facilitate the criti-
cal process of SAR. Using genetic mouse models (Figure 6A) and 
in vitro assays, we describe a novel mechanism whereby lymphat-
ic mimicry of SA endothelial cells render them poised to respond 
to uNK-secreted lymphangiogenic factors to promote vascular 
remodeling (Figure 6B). uNK-derived VEGFC binding to VEGFR3 
in SAs directly activates the receptor, triggering autophosphoryla-
tion and downstream signaling, including ERK phosphorylation. 
Ultimately, this work identifies a novel endothelium-mediated 
mechanism by which the placenta and maternal immune system 
promote SAR to meet the essential needs of the developing fetus, 
and thereby protect the mother and fetus from the pathological 
origins of preeclampsia.
Our findings show that SAs are adopting lymphatic expression 
to promote SAR in an act of lymphatic mimicry. The term lymphat-
ic mimicry is often thought of in cases of nonlymphatic endothelial 
cells exhibiting aberrant lymphatic expression in response to a dis-
ease state or diseased tissue such as a cancerous lesion (39). Howev-
er, a couple examples of programmed postnatal lymphatic mimicry 
have been identified in vessels described as hybrid in their identity. 
This dismantled the previously held belief that programmed initi-
ation of endothelial lymphatic identity in vessels is exclusive to the 
Figure 4. Conditioned media from uNK cells 
activates VEGFR3. (A) Representative images 
of p-VEGFR3 staining in treated LECs. Scale 
bar: 20 μm. (B) Quantification of p-VEGFR3 
MFI in LECs of each treatment group (n = 7 
experiments, 1-way ANOVA with Bonferroni 
posttest). The red horizontal line represents 
the mean. **P < 0.01; ***P < 0.001 versus 
control.
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embryonic development of the lymphatic vasculature. Schlemm’s 
canal of the eye, which is important for draining excess aqueous 
humor, was first described by 2 independent groups as a hybrid 
vessel expressing a combination of blood and lymphatic markers 
(5, 6). Additionally, the vasa recta, which runs along the nephron 
in the kidney to help concentrate urine, was found to express the 
lymphatic markers PROX1 and VEGFR3 (7). Similar to SAs, these 
hybrid vessels acquire lymphatic expression to help the vessels 
perform their highly specialized functions. Unlike the Schlemm’s 
canal and vasa recta, the SAs are not fenestrated nor specialized for 
fluid homeostasis, and while SAs and the vasa recta are both blood 
vessels, lymphatic expression in SAs is novel because they are post-
natal arteries. This is unusual because lymphatic vessels have his-
torically been considered to have a venous origin, and that a venous 
identity is the base upon which lymphatic identity is built (40). 
However, recent work in dermal, mesenteric, and cardiac lymphat-
ic vasculatures prove that not all LECs are venous derived (41). It 
is possible that the role of lymphatic expression in SAs is distinct 
from other hybrid vessels because it is influenced by the existing 
arterial identity. However, it is noteworthy that prior to lymphatic 
expression, the SAs exhibit a change in the expression of the recep-
tor tyrosine kinase EPHB4 and the transmembrane ligand EFNB2, 
markers of veins and arteries respectively, that indicate a shift 
toward a venous identity that may be more permissible for the ini-
tiation of lymphatic expression (13). Indeed, lymphatic vessels can 
also express both EPHB4 and EFNB2, and the activation of EFNB2 
by EPHB4 helps facilitate the internalization of activated VEGFR3 
to initiate downstream signaling (14). While EFNB2 was found to 
be expendable for embryonic blood vascular remodeling, it was 
required for lymphatic remodeling (15). The timing of EFNB2 
expression suggests that the SA endothelium may be grooming 
itself for VEGFR3 signaling just prior to its expression.
By adulthood, VEGFR3 is primarily restricted to lymphatic 
vessels where it helps lymphatic endothelia grow and maintain 
their identity in conjunction with PROX1 (42). However, in addi-
tion to expression in the vasa recta and other fenestrated endo-
thelia, VEGFR3 has also been implicated in adult blood vessel–
sprouting angiogenesis (43) and is aberrantly expressed in the 
proliferating blood vessels of diseased tissue, including tumors 
(44, 45). Furthermore, during development VEGFR3 is widely 
expressed in fetal blood vessels and is essential for their devel-
opment (37, 46). However, here we show an important role for 
Figure 5. VEGFC from uNK cells is required for SAR. (A and B) The decidua of Vegfcfl/fl Vav1-Cre mouse E13.5 placentas have a similar uNK cell density 
compared with Vegfcfl/fl placentas as determined by DBA lectin labeling (per genotype, n = 12–14 total placentas from 3 litters with 2–7 placentas from each 
litter, unpaired t test). (C and D) At E13.5, Vegfcfl/fl Vav1-Cre SAs have increased smooth muscle coverage determined by αSMA staining (per genotype, n = 
11–12 total placentas from 3 litters with 3–5 placentas from each litter; unpaired t test). (E–G) In H&E-stained placentas at E13.5, the lumen area of Vegfcfl/fl 
Vav1-Cre SAs was reduced while the relative wall area was increased (per genotype, n = 15–22 total placentas from 3 litters with 4–10 placentas from each 
litter, unpaired t test). All scale bars: 50 μm. In all graphs the red horizontal line represents the mean. **P < 0.01; ***P < 0.001 versus control.
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these biological processes, such as adrenomedullin-CLR signal-
ing, are likely contributing (47, 49). Interestingly, we noted that 
VEGFR3 phosphorylation in lymphatic ECs treated with uNK-
CM was enhanced at cell-cell borders (Figure 4A) where VEGFR3 
could associate with the VE-cadherin mechanosensory complex. 
Thus, uNK cells may also be appropriating this complex to help 
promote remodeling.
Preeclampsia in the mouse does not naturally occur to the 
extent observed in humans, but mouse models of preeclampsia 
exist (31, 33). However, we found that reduced VEGFR3 activity 
was not sufficient to induce preeclampsia in mice. Though given 
the differences between mice and humans, we might not have 
expected the phenotype to be more severe than that observed in 
uNK-deficient mice, which are not reported to get preeclampsia. 
Instead, mice deficient for uNK cells are reported to exhibit fetal 
growth restriction, same as we observed in Flt4Chy/+ pregnancies 
(Figure 3, I–K). This suggests that, while Flt4Chy/+ pregnancies may 
not be a model of preeclampsia, they may be useful as model of 
defective SAR, which contributes to fetal growth restriction simi-
lar to uNK-deficient mice, due to endothelial cell signaling insuf-
ficiency rather than immunodeficiency. Interestingly though, 
women with preeclampsia were found to have reduced endothe-
VEGFR3 in an adult blood vessel where we historically would not 
have expected to find its expression. We show that VEGFR3 func-
tions as a promotor of vessel remodeling in SAs. Recently, the role 
VEGFR3 in vascular remodeling has come under the spotlight. 
It was found that VEGFR3 is responsive to shear stress and that 
its activation promotes vascular remodeling (47). Also, zebrafish 
with reduced VEGFR3 expression have a dose-dependent reduc-
tion in aorta diameter (47). This is attributed to the association 
of VEGFR3 with the VE-cadherin mechanosensory complex at 
cell-cell junctions that activates by a VEGFC-independent, c-Src–
mediated mechanism (48, 49). In contrast, we show VEGFR3 
activation in SAR is VEGFC-dependent, but we suspect the pro-
cess to be multifactorial and that other factors may make some 
VEGFC-independent contributions. For example, uNK cells also 
secrete ANGPT1, ANGPT2, and IFN-γ, which can help disrupt 
the cell integrity of vascular smooth muscle cells, and MMPs that 
degrade extracellular matrix, potentiating smooth muscle regula-
tion of SAs (25). In particular, IFN-γ from uNK cells was found to 
be necessary for SAR, but it is not yet clear if it functions concur-
rently or in interaction with VEGFR3 signaling (50). Also, shear 
stress and extracellular matrix are evolving dynamics in SAs 
during placental development, so signaling pathways that control 
Figure 6. A model of VEGFR3 activation in SAs. (A) Graphical representation of the mechanisms by which the mouse models examined in this study affect 
VEGFR3 signaling and SAR. (B) Mechanism of lymphatic mimicry to promote SAR. During SAR, endothelial cells acquire a hybrid vessel phenotype becom-
ing more lymphatic-like; expression of certain lymphatic markers is upregulated, SMC layer is reduced, and luminal expansion occurs.
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lymphatic mimicry in SAs provides a convergence point for AM and 
other lymphatic signaling pathways to protect the developing pla-
centa from the vascular onset of preeclampsia.
Methods
Please see Supplemental Methods for a detailed explanation of all 
experimental procedures.
Study approval. All experiments were approved by the IACUC of 
the University of North Carolina at Chapel Hill.
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lial VEGFR3 expression in their spiral arteries (51), suggesting 
that VEGFR3 may play an expanded role in human pregnancy not 
observable in mice.
Some fundamental differences in mouse and human placen-
tas must be taken into consideration. First, in humans there is a 
robust deep invasion of extravillous trophoblast cells into the 
decidua that integrate into and supplant maternal endothelium, 
which occurs far less and more shallow in mice (52). The purpose 
of this invasion is to manipulate SAs to promote further remod-
eling; however, the period of remodeling examined in this study 
precedes when this invasion would occur (53). We found in the rat 
decidua, where robust trophoblast invasion also occurs (54), VEG-
FR3 was still robustly expressed in the SA endothelium, which 
coincided with smooth muscle loss as observed in mice. This is 
also consistent with reports of VEGFR3 expression in human SAs 
(51). This suggests that trophoblast invasion is not an evolution-
ary alternative to the lymphatic mimicry observed in mice. Inter-
estingly, in addition to secreting VEGFC, trophoblasts have been 
reported to acquire VEGFR3 expression after displacing the SA 
endothelium in humans (55), but we did not find this to occur in 
rats. Moreover, the human decidua has lymphatic vessels that are 
absent in the mouse decidua. While mouse trophoblasts had no 
effect on lymphangiogenesis, human trophoblasts were found to 
promote it (21). So it is distinctly possible that human trophoblasts 
contribute a substantial amount of VEGFC, which could rival uNK 
cells as the predominant source of VEGFC promoting SAR.
It will remain of interest to identify pregnancy- and preeclamp-
sia-related factors that capitalize upon lymphatic mimicry to drive 
SAR. For example, our previous work shows that fetal tropho-
blast–derived adrenomedullin (AM) peptide enhances recruitment 
of uNK cells to the decidua and promotes SAR (19). Our findings 
here suggest that AM, which is blunted in women with severe pre-
eclampsia, may effectively be increasing decidual VEGFC via uNK 
cell recruitment. Coincidentally, AM is also a well-established 
angiogenic and lymphangiogenic signaling pathway, which is 
notably enhanced in lymphatic endothelium compared with blood 
endothelium (56). Additionally, PROX1 is a transcriptional regula-
tor of the AM receptor, CLR (56), which is a shear-stress respon-
sive receptor abundantly expressed in SAs (19). So, it is likely that 
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